Analysis of United States Drug Patent 3,801,562
United States Patent 3,801,562, titled "Method of Treating Disorders of the Central Nervous System," issued on April 2, 1974, to Upjohn Co. The patent describes a method for treating central nervous system disorders using 6-alkyl-5-alkenyl-2,4(1H,3H)-pyrimidinediones. The core of the patent lies in the specific chemical structure of the compounds and their therapeutic application, particularly their use as anticonvulsants and sedatives.
What is the core invention of Patent 3,801,562?
The primary invention covered by Patent 3,801,562 is a method of treating disorders of the central nervous system. This treatment involves administering a specific class of chemical compounds identified as 6-alkyl-5-alkenyl-2,4(1H,3H)-pyrimidinediones.
What are the specific chemical compounds claimed?
The patent claims encompass compounds with the following general formula:
- A pyrimidinedione ring at positions 2 and 4.
- An alkyl group at position 6.
- An alkenyl group at position 5.
The specific examples provided in the patent include compounds with varying alkyl and alkenyl chain lengths and saturation. For instance, one exemplified compound is 6-allyl-5-(1-methylallyl)-2,4(1H,3H)-pyrimidinedione.
What central nervous system disorders does the patent claim to treat?
The patent explicitly claims the use of these compounds for treating disorders of the central nervous system. While not exhaustively defined within the abstract, the specification details their efficacy as anticonvulsants and sedatives. This implies applications in conditions such as epilepsy and potentially insomnia or anxiety, though the primary focus appears to be on seizure disorders.
What is the claimed mechanism of action, if any?
The patent's claims are focused on the composition of matter and the method of use. It does not extensively detail a specific molecular mechanism of action. However, the stated therapeutic effects (anticonvulsant, sedative) suggest interaction with neurotransmitter systems within the central nervous system, likely involving GABAergic pathways, which are common targets for such drugs.
What is the scope of the patent claims?
The scope of Patent 3,801,562 is defined by its independent and dependent claims. The independent claims broadly cover the method of treatment, while dependent claims add specific limitations.
What are the key independent claims?
The key independent claims define the method of treatment using the defined chemical compounds. Claim 1, a representative independent claim, describes "A method of treating disorders of the central nervous system which comprises administering to a subject in need of such treatment a therapeutically effective amount of a 6-alkyl-5-alkenyl-2,4(1H,3H)-pyrimidinedione."
What are the limitations introduced by dependent claims?
Dependent claims refine the scope by specifying particular types of alkyl and alkenyl groups, preferred compounds, or specific therapeutic applications. For example, dependent claims might limit the alkyl group to methyl or ethyl, or the alkenyl group to a specific number of carbon atoms or unsaturation patterns. They can also specify the dosage range or the route of administration.
How do the claims relate to specific therapeutic uses?
The claims broadly cover the "treatment of disorders of the central nervous system." However, the specification provides context for these disorders, highlighting anticonvulsant and sedative properties. This means the claims are directed towards the use of the defined pyrimidinediones for managing conditions characterized by excessive neural excitability or lack of sleep.
What is the patent landscape surrounding Patent 3,801,562?
The patent landscape for a drug from 1974 is characterized by its expired status, the potential for generic competition, and its historical significance in relation to later developments in CNS drug discovery.
When did Patent 3,801,562 expire?
United States patents typically have a term of 17 years from the date of grant or 20 years from the filing date, whichever is longer, prior to the enactment of the Uruguay Round Agreements Act (URAA) in 1995. For Patent 3,801,562, granted on April 2, 1974, the original term of 17 years would have expired on April 2, 1991. Post-grant extensions, if any were applied for and granted under the Hatch-Waxman Act, could have extended this period. However, without specific extension data, the original expiration date is the primary reference point.
Are there any related patents or later-generation compounds?
Yes, the development of CNS drugs is a continuous process. Following the discovery of the compounds in Patent 3,801,562, subsequent research likely led to the development of:
- Analogues and Derivatives: Chemists would have synthesized and patented compounds with structural modifications to improve efficacy, reduce side effects, or alter pharmacokinetic properties.
- Improved Formulations: Patents might exist for novel drug delivery systems or formulations of these pyrimidinediones to enhance their therapeutic profiles.
- New Therapeutic Uses: Further research could have identified new applications for these or structurally related compounds beyond the initial scope claimed in 1974.
Identifying specific successor patents would require a comprehensive patentability search focusing on the chemical structure and therapeutic uses.
What is the status of generic competition for drugs based on this patent?
Given the expiration of Patent 3,801,562, any drug molecules that fall strictly within its claims and were the subject of commercialization under this patent are eligible for generic production. The market availability of generic versions depends on the existence of approved New Drug Applications (NDAs) or Abbreviated New Drug Applications (ANDAs) for specific drug products utilizing these compounds.
How does this patent inform current R&D strategies?
For R&D, Patent 3,801,562 serves as a foundational disclosure of a chemical class with CNS activity. It highlights:
- Chemical Space: The pyrimidinedione scaffold with specific alkyl and alkenyl substitutions.
- Therapeutic Area: The potential for this class of compounds in anticonvulsant and sedative therapies.
- Historical Precedent: Understanding early research in this area can inform strategies to develop novel compounds by addressing limitations of older drugs or by exploring related but distinct chemical spaces.
This patent acts as a reference point in the historical development of CNS therapeutics.
What are the implications for businesses?
The implications of Patent 3,801,562 for businesses are primarily related to its expired status and the scientific information it discloses.
What is the significance of the patent being expired?
The expiration of Patent 3,801,562 means that the specific method of treatment and composition of matter described therein are no longer protected by patent law. This allows:
- Generic Manufacturers: To produce and market drugs falling within the patent's claims, provided they meet regulatory approval.
- New Drug Development: To use the disclosed chemical structures as a starting point for developing new, patentable analogues or improved therapies.
- Research: To freely utilize the scientific information contained within the patent without infringing on exclusive rights.
How can companies leverage the information in this patent?
Companies can leverage the information in Patent 3,801,562 in several ways:
- Informed R&D: Use the disclosed chemical structures and their demonstrated CNS activity as a basis for designing next-generation therapeutics. This could involve modifying the core structure to improve efficacy, safety, or pharmacokinetic properties, leading to new patentable inventions.
- Freedom-to-Operate Analysis: Understanding the claims of expired patents is crucial for freedom-to-operate analyses. It clarifies what previously protected intellectual property is now in the public domain, reducing the risk of infringement for new product development.
- Historical Context: For companies involved in developing CNS drugs, this patent provides historical context for the therapeutic area and the chemical scaffolds that were explored. This can inform strategic decisions about where to focus R&D efforts.
- Target Identification: If the compounds in the patent have a well-understood mechanism of action, this information can inform target validation for new drug discovery programs.
Are there any opportunities for new patent filings related to this technology?
Yes, opportunities for new patent filings exist, but they would not be for the original invention itself. Instead, new patents could be sought for:
- Novel Analogues: Synthesizing and patenting new chemical entities that are structurally related but distinct from the compounds claimed in Patent 3,801,562. These new compounds would require demonstrating novelty, non-obviousness, and utility.
- Improved Formulations: Developing new drug delivery systems or formulations (e.g., extended-release, targeted delivery) for existing or novel pyrimidinedione compounds.
- New Therapeutic Uses: Discovering and patenting new medical uses for the pyrimidinedione compounds or their derivatives, provided these uses are not obvious from the prior art.
- Manufacturing Processes: Developing novel, more efficient, or environmentally friendly methods for synthesizing the pyrimidinedione compounds.
Key Takeaways
United States Patent 3,801,562, granted in 1974, covers a method for treating central nervous system disorders using 6-alkyl-5-alkenyl-2,4(1H,3H)-pyrimidinediones. The patent's claims are focused on the chemical structure and therapeutic application, particularly as anticonvulsants and sedatives. The patent expired around 1991, removing patent protection for the disclosed inventions. This expiration opens avenues for generic competition and allows businesses to leverage the disclosed chemical space and therapeutic insights for future R&D. Opportunities for new patent filings exist for novel analogues, improved formulations, new therapeutic uses, and advanced manufacturing processes, rather than the original claims.
Frequently Asked Questions
1. Can a company manufacture a drug based on the exact chemical structure in Patent 3,801,562 today?
Yes, assuming no other valid patents or regulatory exclusivities (such as orphan drug exclusivity or pediatric exclusivity) are in force, a company can manufacture and market drugs that fall within the claims of Patent 3,801,562, as the patent has expired. Regulatory approval from agencies like the FDA would still be required.
2. Does the expiration of this patent mean all drugs containing these compounds are generic?
The expiration of the patent means the underlying invention is no longer protected. However, specific drug products might have separate patents covering formulation, manufacturing processes, or new uses that could still be in force. A thorough freedom-to-operate analysis is necessary for each specific product.
3. What is the typical lifecycle of a drug patent like this?
A drug patent, especially from the pre-URAA era, typically lasted 17 years from grant. For a patent granted in 1974, this would be approximately 1991. If the drug product was approved later, additional patent term extensions (PTE) under the Hatch-Waxman Act could have been granted, extending protection.
4. What is the difference between a patent for a compound and a patent for a method of treatment?
A patent for a compound protects the chemical entity itself. A patent for a method of treatment protects the specific way a known compound is used to treat a particular condition. In Patent 3,801,562, the primary claims are for the method of treatment, though the claims implicitly cover the use of the disclosed compounds.
5. Where can I find information about patents that might have followed Patent 3,801,562?
Patent databases such as the USPTO's Patent Public Search, Google Patents, Espacenet, and commercial patent search platforms can be used. Searching for the original patent number, inventor names, assignee names, or chemical structure keywords related to 6-alkyl-5-alkenyl-2,4(1H,3H)-pyrimidinediones would help identify subsequent related patents.
Citations
[1] Upjohn Co. (1974). United States Patent 3,801,562: Method of treating disorders of the central nervous system. U.S. Patent and Trademark Office.
